亚庇国际研究

Indena是一家致力于识别、开发和生产的活动原则来源于植物,用于制药、保健食品和化妆品行业。Indena、民营意大利公司约有700名员工,其中包括10%致力于全职研究,旨在培养管理,制造、分销业务在全世界40多个国家。Indena成功的关键是它的研究,包括:药用植物的药理筛选的好处;识别新的活跃的原则;提取和纯化系统的开发和工业应用的前沿。phyto-chemical研究进行Indena Settala自己的研究中心,意大利。Indena同样也与世界上最著名的大学和私人研究机构在生物的安全性和有效性临床评估阶段i的主要战略目标之一的医药研究开发新的积极的原则的应用程序。这也是一个不可缺少的保健食品和化妆品行业的基础。在制药行业Indena目前专注于抗癌治疗的发展,紫杉醇的成功后,以及在抗菌和抗病毒药物。还在研究是活跃的原则治疗病态和中枢神经系统功能障碍,如抑郁,焦虑,阳痿,睡眠障碍、感觉过敏。 Today Indena is also concentrating its efforts on the industrial production of high-quality standardised active principles derived from plants, which are important ingredients in health food products. In fact, the company produces standardised extracts from edible plants that are traditionally recognised as having therapeutic properties, as well as from plants that have proven pharmacological value. Indena's research and production activities are particularly attentive to plant-based principles that have anti-oxidant properties and are effective in preventing damage caused by free radicals. Backed by over 80 years of botanical experience, the Italian company has developed a plantation network, managed by experts, to supply its research and production centers with officinal plants, while at the same time ensuring bio-diversity and protecting the ecosystem balance from uncontrolled harvesting. Today more than 60% of the raw material used in the manufacturing process comes from cultivation. Indena's decades-long global presence in the plant extraction industry is a guarantee of its in-depth knowledge and understanding of the business, market trends and legal considerations, through constant communication and interaction between the company's experts and the major international regulatory authorities such as WHO, EMEA, and ESCOP, and main pharmacopoeias.

国际医药制药服务的提供者。它专门从事制药配方开发、制造和销售。医疗保健行业的公司服务客户。它成立于1977年,位于艾哈迈达巴德,印度。

选择研究伯明翰公司管理的临床开发试验。

Onepharm研究和开发提供了一个从药用植物产品隔离,与抗炎活性

Inflabloc制药公司从事研究和开发药物治疗炎症性疾病。Inflabloc目前的产品开发是基于这些发现强烈的抗炎作用的脱氢表雄酮(DHEA),一个在肾上腺类固醇。公司的主要产品是脱氢表雄酮联合治疗。公司有4个产品的开发。ip - 1001将进入第二阶段的临床试验在今年晚些时候在克罗恩病。ip - 1002已完成第一阶段。ip - 1003最近建立了概念在炎症性肠病(IBD)动物模型,而ip - 1005刚刚进入概念验证测试中c反应蛋白(CRP)小鼠模型。

Fermalogic从事工业微生物学与专业化研究和开发基因工程发酵微生物的发展新的医药产品和过程改进。